Published in Ann Surg on May 01, 2015
Feasibility of Molecular Biology in Pancreatic Cyst Tumors (CYST-GEN) | NCT03305146
Therapeutic Approach to Cystic Neoplasms of the Pancreas. Surg Oncol Clin N Am (2016) 0.84
Pancreatic cystic neoplasms: Review of current knowledge, diagnostic challenges, and management options. J Carcinog (2015) 0.83
Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management. Am J Gastroenterol (2017) 0.79
Cystic Neoplasm of the Pancreas. Indian J Surg (2015) 0.75
Pancreatic resection for intraductal papillary mucinous neoplasm- a thirteen-year single center experience. BMC Cancer (2016) 0.75
Intracystic Biopsy and Diagnosis of Intraductal Papillary Mucinous Neoplasm via SpyGlass Pancreatoscopy. Ochsner J (2015) 0.75
Natural History of Pancreatic Cysts. Dig Dis Sci (2017) 0.75
Successful ablation of lymph nodes using irreversible electroporation (IRE) in a porcine survival model. Langenbecks Arch Surg (2017) 0.75
Surgical Management of Pancreatic Cysts: A Shifting Paradigm Toward Selective Resection. Dig Dis Sci (2017) 0.75
Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery (2005) 16.42
International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology (2006) 8.83
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22
Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg (2004) 5.09
Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology (2007) 2.96
Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg (2001) 2.80
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg (1999) 2.33
Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut (2011) 1.94
Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol (2009) 1.90
Pancreatic resections for cystic neoplasms: from the surgeon's presumption to the pathologist's reality. Surgery (2012) 1.76
Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms. Am J Surg Pathol (2008) 1.68
851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery (2012) 1.68
Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types. Am J Surg Pathol (2006) 1.46
Pancreatic cystic neoplasms: management and unanswered questions. Gastroenterology (2013) 1.39
Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut (2010) 1.35
Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan. Pancreas (2011) 1.31
Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg (2007) 1.30
Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas (2011) 1.25
Intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology (2010) 1.13
Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg (2011) 1.07
Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable: a prospective evaluation. Ann Surg (2005) 1.04
Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. J Gastroenterol (2011) 1.02
Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg (2013) 0.98
Pathohistological subtype predicts survival in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg (2013) 0.97
Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg (2010) 0.96
Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram. Ann Surg Oncol (2013) 0.93
Evaluation of clinical meaning of histological subtypes of intraductal papillary mucinous neoplasm of the pancreas. Pancreas (2013) 0.93
Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery (2010) 0.91
Prognostic relevance of pathologic subtypes and minimal invasion in intraductal papillary mucinous neoplasms of the pancreas. Tumour Biol (2010) 0.90
Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence. Am J Surg Pathol (2004) 0.90
Predictors of malignancy and natural history of main-duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas (2011) 0.90
Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. Surgery (2014) 0.87
Prevalence of malignancy in patients with pure main duct intraductal papillary mucinous neoplasms. Gastrointest Endosc (2013) 0.79
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
International network of cancer genome projects. Nature (2010) 20.35
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology (2004) 6.75
Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg (2002) 6.24
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg (2004) 5.09
Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg (2003) 4.86
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas (2011) 4.56
Cystic neoplasms of the pancreas. N Engl J Med (2004) 3.89
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Hepatic portal venous gas: the ABCs of management. Arch Surg (2009) 3.76
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery (2007) 3.42
In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology (2007) 3.41
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39
Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg (2007) 3.38
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol (2006) 3.37
Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 3.28
Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology (2007) 2.96
Comprehensive microscopy of the esophagus in human patients with optical frequency domain imaging. Gastrointest Endosc (2008) 2.94
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg (2015) 2.79
Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics (2009) 2.79
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.65
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res (2009) 2.62
The impact of the 80-hour resident workweek on surgical residents and attending surgeons. Ann Surg (2006) 2.59
Surgical management of bile duct injuries sustained during laparoscopic cholecystectomy: perioperative results in 200 patients. Ann Surg (2005) 2.58
Intraepithelial lymphocytosis in architecturally preserved proximal small intestinal mucosa: an increasing diagnostic problem with a wide differential diagnosis. Arch Pathol Lab Med (2006) 2.46
Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg (2008) 2.45
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg (2004) 2.35
Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol (2009) 2.35
Autoimmune pancreatitis: imaging features. Radiology (2004) 2.34
Identifying intestinal metaplasia at the squamocolumnar junction by using optical coherence tomography. Gastrointest Endosc (2006) 2.31
Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch Pathol Lab Med (2009) 2.30
Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg (2004) 2.29
Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg (2005) 2.27
Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg (2013) 2.26
American Surgical Association Blue Ribbon Committee Report on Surgical Education: 2004. Ann Surg (2005) 2.25
Implications and cost of pancreatic leak following distal pancreatic resection. Arch Surg (2006) 2.25
Incidental pancreatic cysts: do we really know what we are watching? Pancreatology (2010) 2.22
Surgical privileging and credentialing: a report of a discussion and study group of the American Surgical Association. J Am Coll Surg (2009) 2.18
Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg (2007) 2.10
Major bile duct injuries associated with laparoscopic cholecystectomy: effect of surgical repair on quality of life. Ann Surg (2002) 2.09
Identification of surgical complications and deaths: an assessment of the traditional surgical morbidity and mortality conference compared with the American College of Surgeons-National Surgical Quality Improvement Program. J Am Coll Surg (2006) 2.07
Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery (2006) 2.07
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res (2010) 2.03
ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol (2009) 2.01
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med (2013) 1.98
Residency training in surgery in the 21st century: a new paradigm. Surgery (2004) 1.94
Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut (2011) 1.94
Assessment of pancreatic cancer care in the United States based on formally developed quality indicators. J Natl Cancer Inst (2009) 1.92
Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol (2009) 1.90
A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg (2006) 1.89
Angiotensin II drives the production of tumor-promoting macrophages. Immunity (2013) 1.88
Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist (2012) 1.88
A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg (2010) 1.83
Resected serous cystic neoplasms of the pancreas: a review of 158 patients with recommendations for treatment. J Gastrointest Surg (2007) 1.83
Autoimmune pancreatitis: more than just a pancreatic disease? A contemporary review of its pathology. Arch Pathol Lab Med (2005) 1.80
Image-guided biopsy in the esophagus through comprehensive optical frequency domain imaging and laser marking: a study in living swine. Gastrointest Endosc (2009) 1.79
Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. Gastroenterology (2009) 1.78
Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg (2011) 1.78
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist (2013) 1.76
Hospital readmission after pancreaticoduodenectomy. J Gastrointest Surg (2006) 1.73
Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experience. Arch Surg (2010) 1.72
Implications and management of pancreatic fistulas following pancreaticoduodenectomy: the Massachusetts General Hospital experience. Arch Surg (2008) 1.72
EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas (with video). Gastrointest Endosc (2006) 1.69
Debridement and closed packing for sterile or infected necrotizing pancreatitis: insights into indications and outcomes in 167 patients. Ann Surg (2008) 1.69
Volumetric optical frequency domain imaging of pulmonary pathology with precise correlation to histopathology. Chest (2013) 1.68
851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery (2012) 1.68